Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 13, 2007Journal of Clinical MicrobiologyOpen Access

Treatment with Tigecycline of Recurrent Urosepsis Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

View Full Paper
Ask AI
Bookmark
Share

Authors

WKWolfgang A. KruegerAbbVie (United States)VKVolkhard A. J. KempfGoethe University FrankfurtMPManou Peiffer

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Krueger et al. (2007) studied this question.

synapsesocial.com/papers/6a6fb021f44fa9f079dd291ahttps://doi.org/10.1128/jcm.01340-07
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation of Meropenem Plasma Levels with Pharmacodynamic Requirements in Critically Ill Patients Receiving Continuous Veno-Venous Hemofiltration2003 · 58 citations
  2. 2The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline2005 · 188 citations
  3. 3Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers2005 · 107 citations
  4. 4Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration1998 · 84 citations